AXSM Q4 2022 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M

Gross Profit

$22M90.6% margin

Operating Income

-$60M-245.8% margin

Net Income

-$61M-251.3% margin

EPS (Diluted)

$-1.41

QoQ Revenue Growth

+44.7%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$331M

Total Liabilities

$222M

Stockholders' Equity

$110M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$0	—
Gross Profit	$22M	$0	—
Operating Income	-$60M	-$33M	-83.7%
Net Income	-$61M	-$34M	-80.2%